Ledipasvir, Sofosbuvir
Indications
Ledipasvir, Sofosbuvir is used for:
LEDIPASVIR
Ledipasvir in combination with sofosbuvir, or in combination with sofosbuvir and ribavirin, is indicated for the treatment of chronic hepatitis c (chc) genotype 1 infection in adults
SOFOSBUVIR
Sofosbuvir is used in combination therapy to treat chronic hepatitis c virus (hcv) infected patients with hcv genoptype 1,2,3, or 4, and to treat hcv and hiv co-infected patients. The combination therapy includes either ribavirin alone or ribavirin and peg-interferon alfa
Ledipasvir in combination with sofosbuvir, or in combination with sofosbuvir and ribavirin, is indicated for the treatment of chronic hepatitis c (chc) genotype 1 infection in adults
SOFOSBUVIR
Sofosbuvir is used in combination therapy to treat chronic hepatitis c virus (hcv) infected patients with hcv genoptype 1,2,3, or 4, and to treat hcv and hiv co-infected patients. The combination therapy includes either ribavirin alone or ribavirin and peg-interferon alfa
Adult Dose
Child Dose
Renal Dose
Administration
Contra Indications
Precautions
Pregnancy-Lactation
Interactions
Adverse Effects
Side effects of Ledipasvir, Sofosbuvir :
Mechanism of Action
LEDIPASVIR
Ledipasvir is an inhibitor of the hepatitis c virus (hcv) ns5a protein required for viral rna replication and assembly of hcv virions. Although its exact mechanism of action is unknown, it is postulated to prevent hyperphosphorylation of ns5a which is required for viral production. It is effective against genotypes 1a, 1b, 4a, and 5a and with a lesser activity against genotypes 2a and 3a of hcv
SOFOSBUVIR
Sofosbuvir is nucleotide analog inhibitor, which specifically inhibits hcv ns5b polymerase. Sofosbuvir prevents hcv viral replication by binding to the two mg2+ ions present in hcv ns5b polymerase's gdd active site motif
Ledipasvir is an inhibitor of the hepatitis c virus (hcv) ns5a protein required for viral rna replication and assembly of hcv virions. Although its exact mechanism of action is unknown, it is postulated to prevent hyperphosphorylation of ns5a which is required for viral production. It is effective against genotypes 1a, 1b, 4a, and 5a and with a lesser activity against genotypes 2a and 3a of hcv
SOFOSBUVIR
Sofosbuvir is nucleotide analog inhibitor, which specifically inhibits hcv ns5b polymerase. Sofosbuvir prevents hcv viral replication by binding to the two mg2+ ions present in hcv ns5b polymerase's gdd active site motif